Heron Therapeutics, Inc. HRTX
Set alert
As of Nov 2, 3:52 PM ET
- YTD
- -77.54%
- 1 year
- -74.83%
- Open
- 0.2799
- Prev close
- 0.2777
- Mkt cap
- 55.17M
- Vol
- 1.09M
- Avg vol
- 2.48M
- EPS
- -0.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.275
- High
- 0.2995
- Forward P/E
- 0.00
- Beta
- 1.81
- Short ratio
- 14.20
- Inst. own
- 81.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.57
- 200-d avg
- 2.42
- 1y target
- 6.00
News
6 days ago globenewswire.com
Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
CARY, N.C., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host…
-
1 month ago benzinga.com
Heron Therapeutics Enters Multi-product Development And License Agreement On Sept 23, 2026; Granted Exclusive License To Market Products In U.S.; Co To Pay Milestone And Royalty Payments Under License Agreement
On September 23, 2026 (the "Effective Date"), Heron Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a multi-product Development and License Agreement (the "License
1 month ago defenseworld.net
Head-To-Head Review: Heron Therapeutics (NASDAQ:HRTX) vs. Sol-Gel Technologies (NASDAQ:SLGL)
Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Heron Therapeutics (NASDAQ: HRTX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
2 months ago seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
2 months ago marketbeat.com
Heron Therapeutics Q2 Earnings Call Highlights
Heron Therapeutics NASDAQ: HRTX reported second-quarter net revenue of $37.7 million, up from $34.7 million in the first quarter and $37.2 million in the comparable prior-year period, while…
-
2 months ago benzinga.com
Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.01) by Infinity percent. This is a 50 percent decrease over losses…
3 months ago globenewswire.com
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host…
3 months ago zacks.com
New Strong Sell Stocks for July 15th
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
5 months ago benzinga.com
Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrades, visit analyst ratings page.
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Heron Therapeutics, Lowers Price Target to $2
HC Wainwright & Co. analyst Brandon Folkes maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $2.
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
5 months ago benzinga.com
Heron Therapeutics To Appeal Delaware Court Ruling Invalidating Two CINVANTI Patents In Litigation With Azurity
Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a…
5 months ago globenewswire.com
U.S. District Court Issues Decision Regarding CINVANTI® Patents
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
5 months ago seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
5 months ago marketbeat.com
Heron Therapeutics Q1 Earnings Call Highlights
Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving…
5 months ago zacks.com
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall…
5 months ago zacks.com
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
5 months ago globenewswire.com
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the…
6 months ago zacks.com
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 months ago globenewswire.com
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host…
6 months ago zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
8 months ago seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
8 months ago zacks.com
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key…
8 months ago benzinga.com
Earnings Breakdown: Heron Therapeutics Q4
Earnings Breakdown: Heron Therapeutics Q4
8 months ago globenewswire.com
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
– ZYNRELEF ® and APONVIE ® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise – Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to…
-
8 months ago benzinga.com
Earnings Scheduled For February 26, 2026
Earnings Scheduled For February 26, 2026
8 months ago seekingalpha.com
Heron: Near The Bottom Of A Trading Range Despite Positives
HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in…
-
9 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Heron Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $6 price target.
-
9 months ago benzinga.com
Heron Therapeutics Reports Q4 Preliminary Net Revenue Of ~$40.5M, ~$154.9M For 2025
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue.Net…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
11 months ago benzinga.com
Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the inclusion of APONVIE® (aprepitant) injectable emulsion in the newly…
-
12 months ago benzinga.com
UPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 166.67 percent. This is a 33.33 percent decrease over losses…
-
12 months ago benzinga.com
Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $156.482M Est
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $156.482 million estimate.
-
12 months ago benzinga.com
Heron Therapeutics Q3 EPS $(0.10) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.01) by 900 percent. This is a 233.33 percent decrease over losses of…
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
1 year ago benzinga.com
Heron Therapeutics Adopts Section 382 Rights Plan To Protect Nols And Tax Attributes; Plan Approved By Board And Satisfies Covenant Under Note Agreement With Rubric Capital
Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights…
-
1 year ago benzinga.com
Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $3
Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $4 to $3.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
Heron Therapeutics Affirms FY2025 Sales Guidance of $153.000M-$163.000M vs $158.538M Est
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.000 million-$163.000 million to $153.000 million-$163.000 million vs $158.538 million estimate.
-
1 year ago benzinga.com
Heron Therapeutics Q2 EPS $(0.02) Misses $(0.01) Estimate, Sales $37.200M Miss $38.075M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 53.85 percent. This is a 66.67 percent increase over losses…
1 year ago benzinga.com
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
-
1 year ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $6
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy rating and announces Price Target of $6.
-
1 year ago benzinga.com
Heron Therapeutics Affirms FY2025 Sales Guidance of $153.00M-$163.00M vs $157.27M Est
Heron Therapeutics (NASDAQ:HRTX) affirms FY2025 sales outlook from $153.00 million-$163.00 million to $153.00 million-$163.00 million vs $157.27 million estimate.
-
1 year ago benzinga.com
Heron Therapeutics Q1 EPS $0.01 Beats $(0.01) Estimate, Sales $38.90M Beat $37.42M Estimate
Heron Therapeutics (NASDAQ:HRTX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 200 percent. This is a 150 percent increase over losses of…